sorafenib has been researched along with pyrene in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pyrene) | Trials (pyrene) | Recent Studies (post-2010) (pyrene) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,163 | 3 | 1,072 |
| Protein | Taxonomy | sorafenib (IC50) | pyrene (IC50) |
|---|---|---|---|
| Cytochrome P450 1A1 | Homo sapiens (human) | 0.041 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.007 | |
| Cytochrome P450 1B1 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, HJ; Hong, HE; Hong, TH; Jeena, MT; Kim, KH; Kim, OH; Kim, SJ; Lee, KH; Ryu, JH | 1 |
1 other study(ies) available for sorafenib and pyrene
| Article | Year |
|---|---|
Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mitochondria; Organophosphorus Compounds; Peptides; Phenylalanine; Pyrenes; Reactive Oxygen Species; Sorafenib | 2021 |